6 unknown, 5 recruiting, 3 completed, 3 terminated. 16 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 1.
Follow SOX: new trials by email Literature Review of SOX trials Research Report on SOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis HIPEC, SOX, Immune Checkpoint Inhibitors - Gastric Cancer | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 34 | 2025-02-15 | 2025-04-11 |
| Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer Oxaliplatin With S-1 (SOX) Combined H. Pylori Eradication (Amoxicillin + clarithromycin + omeprazole + colloidal bismuth subcitrate), Oxaliplatin With S-1 （SOX） - Chemotherapy Effect | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 198 | 2024-12-31 | 2026-08-06 |
| A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer Tislelizumab, SOX, HIPEC - Gastric Cancer, Gastroesophageal Junction Cancer | Recruiting | Southwest Hospital, China | 122 | 2024-12-01 | 2025-01-07 | |
| Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC Serplulimab, Trastuzumab, Oxaliplatin + Tegafur - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 42 | 2024-07-15 | 2024-06-03 |
| AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer Cadonilimab, Ivonescimab, XELOX - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Harbin Medical University | 50 | 2024-04-10 | 2024-06-27 |
| PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery SOX, XELOX, PD-1 antibody - MSI-H, PD-1 Immunotherapy | Phase 2 | Active not recruiting | Fudan University | 94 | 2022-08-01 | 2026-08-11 |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. Bemarituzumab, CAPOX, SOX - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | Amgen | 72 | 2022-05-17 | 2026-07-29 |
| S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma Oxaliplatin+S-1, Sinitilimab+oxaliplatin+S-1 - Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 302 | 2021-09-01 | 2021-08-04 |
| Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Camrelizumab, SOX, Surgery - Stomach Neoplasms, Digestive System Neoplasms | Phase 2 | Active not recruiting | The Second Affiliated Hospital of Fujian Medical University | 29 | 2020-09-16 | 2023-09-28 |
| A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer SIB-IMRT, S-1, SOX - Gastric Cancer, Neoadjuvant Therapy | Phase 2 | Unknown | Jing Jin, M.D. | 82 | 2019-11-20 | 2022-01-24 |
| An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers BMS-986213, Nivolumab, XELOX - Gastric Cancer, Cancer of the Stomach | Phase 2 | Completed | Bristol-Myers Squibb | 274 | 2018-10-16 | 2025-02-05 |
| Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer FLOT Chemotherapy, SOX Chemotherapy - Gastric Cancer, Chemotherapy Effect | Phase 2 | Completed | Ruijin Hospital | 74 | 2018-08-24 | 2025-07-23 |
| HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer exploratory laparoscopy or laparotomy, HIPEC, Systemic chemotherapy - Peritoneal Metastases From Gastric Cancer | Not applicable | Terminated | Wuhan University | 20 | 2018-01-05 | 2020-03-24 |
| Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma SOX - Neuroendocrine Carcinoma | Phase 2 | Unknown | Peking University | 45 | 2017-09-01 | 2017-09-12 |
| Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer Oxaliplatin plus S-1, S-1 only - Gastric Cancer | Phase 3 | Terminated | Peking University Cancer Hospital & Institute | 29 | 2017-04-24 | 2024-12-03 |
| A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma SIB-IMRT, S-1, Surgery - Stomach Neoplasms, Neoadjuvant Therapy | Phase 2 | Completed | Chinese Academy of Medical Sciences | 71 | 2014-01-01 | 2019-10-16 |
| A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer SOX Sequential S-1, SOX, TEGAFOX Sequential S-1. - Gastric Cancer | Phase 2 / Phase 3 | Unknown | LanZhou University | 300 | 2013-05-01 | 2016-06-29 |
| SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer SOX, XELOX - Colorectal Neoplasm | Phase 2 | Unknown | The First People's Hospital of Changzhou | 60 | 2013-01-01 | 2016-08-19 |
| Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer S-1 plus oxaliplatin, S-1 single - Gastric Cancer | Phase 3 | Unknown | Sun Yat-sen University | 724 | 2011-09-01 | 2016-10-25 |
| Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma SOX - Advanced Hepatocellular Carcinoma | Phase 2 | Unknown | Seoul National University Hospital | 38 | 2011-05-01 | 2011-09-07 |
Stomach Neoplasms (12) · Carcinoma, Neuroendocrine (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Stomach Diseases (1)
Sixth Affiliated Hospital, Sun Yat-sen University (2) · Amgen (1) · Bristol-Myers Squibb (1) · Chinese Academy of Medical Sciences (1) · Fudan University (1) · Harbin Medical University (1) · Jing Jin, M.D. (1) · LanZhou University (1) · Peking University (1) · Peking University Cancer Hospital & Institute (1) · Ruijin Hospital (1) · Seoul National University Hospital (1) · Southwest Hospital, China (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Zhengzhou University (1)
China (16) · Singapore (2) · South Korea (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Chile (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Japan (1)
Birendra Kumar Sah, PH D (1) · Changping Wu, M.D. (1) · Chen Li, PH D (1) · Feng Wang (1) · Jiafu Ji, MD (1) · Jun-Sheng Peng, Dr (1) · Kaixiong Tao, PhD (1) · Lei Lian, Ph.D (1) · Xiao Chen, MD (1) · Zhenggang Zhu, PH D (1) · Zhiwei Zhou, PHD (1)
PMID 26028255, PMID 28241187, PMID 28536493, PMID 29506478, PMID 29727332, PMID 31513484, PMID 32251400, PMID 33257672, PMID 35219300, PMID 35574368, PMID 35623069, PMID 35902798, PMID 38400680, PMID 38553594, PMID 38723227, PMID 41181842, PMID 42600610
2018 (1)